143 related articles for article (PubMed ID: 14698147)
21. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
22. Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge.
Murakami Y; Takei M; Shindo K; Kitazume C; Tanaka J; Higa T; Fukamachi H
J Nat Prod; 2002 Mar; 65(3):259-61. PubMed ID: 11908961
[TBL] [Abstract][Full Text] [Related]
23. Secretory leukocyte protease inhibitor, but not alpha-1 protease inhibitor, blocks tryptase-induced bronchoconstriction.
Forteza RM; Ahmed A; Lee T; Abraham WM
Pulm Pharmacol Ther; 2001; 14(2):107-10. PubMed ID: 11273791
[TBL] [Abstract][Full Text] [Related]
24. Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
Mori S; Itoh Y; Shinohata R; Sendo T; Oishi R; Nishibori M
J Pharmacol Sci; 2003 Aug; 92(4):420-3. PubMed ID: 12939527
[TBL] [Abstract][Full Text] [Related]
25. Bivalent inhibition of human beta-tryptase.
Schaschke N; Matschiner G; Zettl F; Marquardt U; Bergner A; Bode W; Sommerhoff CP; Moroder L
Chem Biol; 2001 Apr; 8(4):313-27. PubMed ID: 11325588
[TBL] [Abstract][Full Text] [Related]
26. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep.
Elrod KC; Moore WR; Abraham WM; Tanaka RD
Am J Respir Crit Care Med; 1997 Aug; 156(2 Pt 1):375-81. PubMed ID: 9279212
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase.
Cregar L; Elrod KC; Putnam D; Moore WR
Arch Biochem Biophys; 1999 Jun; 366(1):125-30. PubMed ID: 10334872
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.
Maryanoff BE
J Med Chem; 2004 Feb; 47(4):769-87. PubMed ID: 14761180
[No Abstract] [Full Text] [Related]
29. Design, synthesis and biological activity of a targeted library of potential tryptase inhibitors.
García M; del Rio X; Silvestre S; Rubiralta M; Lozoya E; Segarra V; Fernández D; Miralpeix M; Aparici M; Diez A
Org Biomol Chem; 2004 Jun; 2(11):1633-42. PubMed ID: 15162216
[TBL] [Abstract][Full Text] [Related]
30. Structure of the complex of leech-derived tryptase inhibitor (LDTI) with trypsin and modeling of the LDTI-tryptase system.
Di Marco S; Priestle JP
Structure; 1997 Nov; 5(11):1465-74. PubMed ID: 9384562
[TBL] [Abstract][Full Text] [Related]
31. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
Levell J; Astles P; Eastwood P; Cairns J; Houille O; Aldous S; Merriman G; Whiteley B; Pribish J; Czekaj M; Liang G; Maignan S; Guilloteau JP; Dupuy A; Davidson J; Harrison T; Morley A; Watson S; Fenton G; McCarthy C; Romano J; Mathew R; Engers D; Gardyan M; Sides K; Kwong J; Tsay J; Rebello S; Shen L; Wang J; Luo Y; Giardino O; Lim HK; Smith K; Pauls H
Bioorg Med Chem; 2005 Apr; 13(8):2859-72. PubMed ID: 15781396
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human mast cell tryptase by benzamidine derivatives.
Stürzebecher J; Prasa D; Sommerhoff CP
Biol Chem Hoppe Seyler; 1992 Oct; 373(10):1025-30. PubMed ID: 1418674
[TBL] [Abstract][Full Text] [Related]
33. Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Liang G; Bowen JP
Curr Top Med Chem; 2016; 16(13):1506-29. PubMed ID: 26369819
[TBL] [Abstract][Full Text] [Related]
34. Pyrrole carboxamidine tryptase inhibitors from Leptonychia pubescens.
Yang LK; Ng SP; Flotow H; Yoganathan K; Daramola BO; Soejarto DD; Buss AD; Butler MS
Planta Med; 2005 Nov; 71(11):1071-2. PubMed ID: 16320213
[TBL] [Abstract][Full Text] [Related]
35. A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by Zinc(II).
Janc JW; Clark JM; Warne RL; Elrod KC; Katz BA; Moore WR
Biochemistry; 2000 Apr; 39(16):4792-800. PubMed ID: 10769136
[TBL] [Abstract][Full Text] [Related]
36. Combinatorial approaches towards the discovery of new tryptase inhibitors.
del Fresno M; Fernández-Forner D; Miralpeix M; Segarra V; Ryder H; Royo M; Albericio F
Bioorg Med Chem Lett; 2005 Mar; 15(6):1659-64. PubMed ID: 15745817
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug.
Erba F; Fiorucci L; Pascarella S; Menegatti E; Ascenzi P; Ascoli F
Biochem Pharmacol; 2001 Feb; 61(3):271-6. PubMed ID: 11172730
[TBL] [Abstract][Full Text] [Related]
38. Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors.
Ono S; Kuwahara S; Takeuchi M; Sakashita H; Naito Y; Kondo T
Bioorg Med Chem Lett; 1999 Dec; 9(23):3285-90. PubMed ID: 10612586
[TBL] [Abstract][Full Text] [Related]
39. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor.
Qian X; Zheng B; Burke B; Saindane MT; Kronenthal DR
J Org Chem; 2002 May; 67(11):3595-600. PubMed ID: 12027669
[TBL] [Abstract][Full Text] [Related]
40. Histone-tryptase interaction: H2A N-terminal tail removal and inhibitory activity.
Fiorucci L; Erba F; Ascoli F
Arch Biochem Biophys; 1997 Nov; 347(2):229-34. PubMed ID: 9367529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
